BIOTRONIK is a private, global medical device company that develops products and services to save lives and improve the quality of life for patients with cardiovascular and endovascular diseases. The company has been focusing on patient care for over 50 years.

BIOTRONIK

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Artivion, Inc.

Zimmer Biomet develops and provides medical technology solutions aimed at alleviating pain and improving the quality of life for people around the world. Self-described as committed to advancing healthcare through cutting-edge technology.

Metric
Company Name	BIOTRONIK	Artivion, Inc.	Zimmer Biomet
Symbol		AORT
MSH ID	COM:BIOTRONIK	COM:ARTIVION	EU:ZIMMERBIOMET
Market	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services
Industry	Medical Devices	Medical - Devices	Medical Devices
Country	NL	US	EU
Stage
Employee Count		1.50K
Website	biotronik.com	artivion.com	zimmerbiomet.eu
LinkedIn			zimmerbiomet
Founders

Metric
Market Cap	1.09B
Enterprise Value
Monthly Web Traffic		24.68K
Web Traffic Growth		-0.01
Valuation
Raised Capital

Metric
Revenue		354.00M
Revenue (LTM)
Revenue (NTM)
Gross Profit		213.98M
EBITDA		37.86M
Operating Income		14.79M
Net Income		-30.57M
EPS		-0.75
Diluted EPS		-0.75
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.65
Operating Profit Margin		0.09
EBITDA Margin		0.11
Net Profit Margin		-0.02
Return on Equity		-0.03
Return on Assets		-0.01
Return on Capital Employed		0.05

COM:BIOTRONIK

BIOTRONIK

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-27.81
P/B Ratio		2.51
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		3.18
EV Multiple		138.13

Metric
Days Sales Outstanding		73.35
Days Payables Outstanding		32.70
Days Inventory Outstanding		239.70
Operating Cycle		316.14
Cash Conversion Cycle		277.20
Asset Turnover		0.48

Metric
Operating Cash Flow		18.58M
Free Cash Flow		11.15M
Cash Flow to Debt		0.06
Operating Cash Flow/Sales		0.05
Free Cash Flow Yield		-0.00

Metric
Cash & Equivalents		58.94M
Accounts Receivable		-4.05M
Inventory		81.98M
Goodwill		247.34M
Debt to Capitalization		0.55
Debt to Assets		0.46
Current Ratio		4.86
Quick Ratio		3.16

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.04
R&D to Revenue		0.09
SG&A to Revenue